Molecular details
Biomarker: BRAF known-stat; RAS known-stat
Biomarker criteria: Mandatory
Prescreening: Local
Additional study population requirements: Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor
Inclusion criteria:
Known RAS and BRAF status. Patients with wild-type KRAS tumours must have received prior treatment with an EGFR inhibitor, unless this was not standard of care according to relevant region-specific treatment recommendations.
Known UGT1A1 status, or patient consents to UGT1A1 status testing if unknown.
